Skip to main content
Skip to main content

Method of Treating Multiple Sclerosis with Anti-K6 Antibody

Tech ID:
Principal Investigator:
Michael Blaber
Licensing Manager:

This invention is based on the discovery that modulators of kallikrein 6 can alter pathogenesis of inflammatory cell mediated diseases both within the central nervous system and in the periphery. As a result, modulators of kallikrein 6 can aid in the treatment and prevention of inflammatory conditions such as MS, rheumatoid arthritis, lupus, and asthma. An antibody having specific binding affinity for kallikrein 6 reduced the degree of demyelination and reduced behavioral defects in animal models of multiple sclerosis.